Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.25M Sell
100,100
-50,200
-33% -$2.65M 0.02% 798
2026
Q1
$8.3M Sell
150,300
-100,600
-40% -$5.45M 0.03% 490
2025
Q4
$12.3M Buy
250,900
+145,900
+139% +$6.8M 0.04% 515
2025
Q3
$4.53M Buy
105,000
+88,900
+552% +$3.47M 0.02% 984
2025
Q2
$618K Sell
16,100
-2,500
-13% -$95.5K ﹤0.01% 2465
2025
Q1
$721K Sell
18,600
-136,100
-88% -$4.98M ﹤0.01% 2259
2024
Q4
$5.23M Sell
154,700
-62,800
-29% -$2.26M 0.01% 1040
2024
Q3
$8.89M Buy
217,500
+55,800
+35% +$2.28M 0.02% 763
2024
Q2
$6.23M Sell
161,700
-60,700
-27% -$2.55M 0.01% 1126
2024
Q1
$9.53M Buy
222,400
+168,900
+316% +$6.97M 0.02% 853
2023
Q4
$1.98M Sell
53,500
-300
-0.6% -$10.8K ﹤0.01% 1785
2023
Q3
$1.95M Sell
53,800
-11,600
-18% -$412K 0.01% 1755
2023
Q2
$2.33M Buy
65,400
+35,900
+122% +$1.29M 0.01% 1231
2023
Q1
$1.05M Buy
+29,500
New +$1.03M 0.02% 1138
2022
Q4
Sell
-19,800
Closed -$583K 3357
2022
Q3
$583K Buy
+19,800
New +$750K 0.01% 1357

Other funds holding GSK

Walleye Capital's GSK Position: Q2 2026 in Review

Walleye Capital increased its GSK (GSK) stake by 7.9% in Q2 2026, buying an estimated $1.55M and bringing the position to 402,472 shares worth $21.1M. The position accounts for 0.08% of the portfolio, ranked #237.

Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 12 quarters since. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Walleye Capital held 402,472 shares of GSK worth $21.1M as of Q2 2026.
  • Walleye Capital bought 29,376 GSK shares in Q2 2026, an estimated $1.55M.
  • GSK made up 0.08% of Walleye Capital's portfolio in Q2 2026, its #237 holding.
  • Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 12 quarters since.
  • 1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.